OncoMatch/Leukemia — Acute Myeloid (AML)/NPM1
Leukemia — Acute Myeloid (AML)NPM1 Clinical Trials
NPM1 mutations are the most common single-gene mutation in AML (~30% of cases) and define a favorable-risk subgroup when not co-occurring with FLT3-ITD. NPM1-mutant AML is sensitive to menin inhibitors (revumenib), venetoclax-based combinations, and standard induction. Trials explore NPM1-targeted strategies, MRD-guided treatment de-escalation, and menin inhibitor combinations for newly diagnosed and relapsed disease.
Top recruiting NPM1 Leukemia — Acute Myeloid (AML) trials
Ranked by phase and US site count.
See all trials matched to your profile →A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Janssen Research & Development, LLC
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Kura Oncology, Inc.
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Stichting Hemato-Oncologie voor Volwassenen Nederland
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
Janssen Research & Development, LLC
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Syndax Pharmaceuticals